Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

December 11, 2020December 11, 2020

Recorlev Lessens Cushing’s Symptoms, Eases Depression, SONICS Trial Data Show

News

Recorlev (levoketoconazole), Strongbridge Biopharma’s oral investigational therapy, lessens disease symptoms and depression, and improves quality of life among people with endogenous Cushing’s syndrome, according to data from the Phase ... Read more

November 26, 2020November 26, 2020

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

News, syndicated

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to ... Read more

November 25, 2020November 25, 2020

Rare Case of Cushing’s Disease Due to ‘Collision’ Brain Tumor Reported

News

Researchers report a very rare case of Cushing’s disease in a 34-year-old woman caused by a “collision” brain tumor, a tumor simultaneously consisting of a meningioma and a pituitary adenoma. ... Read more

October 9, 2020October 9, 2020

Topical Steroid Use While on HIV Therapy May Lead to Cushing’s, Case Study Shows

News

Using steroid-based creams to treat skin conditions in the genital area may lead to the fast development of medication-related Cushing’s syndrome in adults with HIV on antiretroviral therapy with ... Read more

August 21, 2020August 21, 2020

Dissolving Hydrocortisone Tablets for CAH May Lead to Higher Dosing, Cushing’s

News

Dissolving hydrocortisone tablets in water for multiple daily dosing to treat congenital adrenal hyperplasia (CAH) in children may result in higher-than-intended dosing and exogenous Cushing’s syndrome — a form ... Read more

July 1, 2020July 1, 2020

Isturisa Effective in Treating Cushing’s Syndrome Other Than Cushing’s Disease, Phase 2 Trial Shows

News

Recordati’s Isturisa (osilodrostat) safely and effectively normalizes urinary levels of cortisol in people with endogenous Cushing’s syndrome other than Cushing’s disease, according to data from a Phase 2 clinical ... Read more

December 6, 2018

Case Series Highlights Importance of Recognizing Discrepancies Between ACTH Blood Results and Clinical Data

News

Recognizing discrepancies between blood tests of adenocorticotropic hormone (ACTH) levels and patients’ clinical data is important for clinicians to avoid unnecessary testing or misdiagnosis, a case series highlights. The study, ... Read more

November 1, 2018

New Phase 3 Data Further Support Recorlev’s Ability to Safely Lower Cortisol Levels in Cushing’s Patients

News

Strongbridge Biopharma released additional positive results from a Phase 3 trial evaluating whether the company’s investigational therapy Recorlev (levoketoconazole) is safe and effective for people with endogenous Cushing’s syndrome. The latest ... Read more

September 28, 2018September 28, 2018

Bilateral Adrenalectomy Negatively Affects Quality of Life in Cushing’s Patients, Study Suggests

News

Bilateral adrenalectomy, in which the adrenal glands are removed, has a bigger negative impact on the quality of life of patients with Cushing’s disease than other treatment options, a ... Read more

August 14, 2018

Recorlev Shows Promise for Endogenous Cushing’s Syndrome, Results Show

News

Recorlev (levoketoconazole) safely and successfully reduces the levels of cortisol in patients with endogenous Cushing’s syndrome, according to top-line results of a Phase 3 clinical trial. Cushing’s syndrome occurs due ... Read more